Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1449

Sort by

Sort Order Select

Journal Articles

Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes

Blood blood.2024027244.

https://doi.org/10.1182/blood.2024027244

Published: 2025

Includes: Supplemental data

Journal Articles

A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Trial in Progress

Nicholas J. Short, Farhad Ravandi, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Musa Yilmaz, Ghayas C. Issa, Regina Abramova, Araceli Isabella Garza, Hagop M. Kantarjian, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 4288.1.

https://doi.org/10.1182/blood-2024-200923

Published: 2024

Journal Articles

Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes

Mehmet Sevki Uyanik, Guillermo Garcia-Manero, Abhishek Maiti, Farhad Ravandi, Kelly S. Chien, Danielle Hammond, Alexandre Bazinet, Heather Schneider, Stephany Hendrickson, Sherry Pierce, Hagop M. Kantarjian, Naveen Pemmaraju, Guillermo Montalban-Bravo

Blood (2024) 144 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2024-207503

Published: 2024

Journal Articles

Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial

Blood (2024) 144 (Supplement 1): 2124.

https://doi.org/10.1182/blood-2024-203864

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3 -Tyrosine Kinase Domain (TKD) Mutations

Blood (2024) 144 (Supplement 1): 841.

https://doi.org/10.1182/blood-2024-204042

Published: 2024

Journal Articles

Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials

Samuel Urrutia, Koji Sasaki, Alex Bataller, Hagop M. Kantarjian, Guillermo Montalban-Bravo, James McCloskey, Elizabeth A. Griffiths, Karen Yee, Amer M. Zeidan, Michael R. Savona, Aram Oganesian, Yuri Sano, Harold N. Keer, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 661.

https://doi.org/10.1182/blood-2024-193274

Published: 2024

Journal Articles

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D'Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei

Blood (2024) 144 (Supplement 1): 215.

https://doi.org/10.1182/blood-2024-207072

Published: 2024

Journal Articles

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 213.

https://doi.org/10.1182/blood-2024-194827

Published: 2024

Journal Articles

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Blood (2024) 144 (Supplement 1): 212.

https://doi.org/10.1182/blood-2024-207106

Published: 2024

Journal Articles

Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

Alex Bataller, Hagop M. Kantarjian, Alexandre Bazinet, Jayastu Senapati, Gautam Borthakur, Nicholas J. Short, Elias Jabbour, Koichi Takahashi, Naval Daver, Ghayas C. Issa, Courtney D. DiNardo, Naveen Pemmaraju, Nitin Jain, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 56.

https://doi.org/10.1182/blood-2024-202620

Published: 2024

Journal Articles

Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1- mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease

Blood (2024) 144 (Supplement 1): 4336.

https://doi.org/10.1182/blood-2024-209462

Published: 2024

Journal Articles

Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update

Blood (2024) 144 (Supplement 1): 4194.

https://doi.org/10.1182/blood-2024-210642

Published: 2024

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2024) 144 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2024-204296

Published: 2024

Journal Articles

Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)

Caitlin R Rausch, Emmanuel Almanza-Huante, Wei-Ying Jen, Guillermo Montalban-Bravo, Farhad Ravandi, Kelly S. Chien, Nicholas J. Short, Naval Daver, Courtney D. DiNardo, Abhishek Maiti, Joseph E. Jabbour, Ghayas C. Issa, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 4262.

https://doi.org/10.1182/blood-2024-203831

Published: 2024

Journal Articles

Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory

Iman Sarami, Ruchi Singhal, Mark Routbort, Koji Sasaki, Daniel Domogala III, Gokce A. Toruner, Shibu Ninan, Nitin Jain, Keyur P. Patel, Elias Jabbour, Hagop M. Kantarjian, Carlos E. Bueso-Ramos, L. Jeffrey Medeiros, Raja Luthra, Guilin Tang, Rashmi Kanagal-Shamanna

Blood (2024) 144 (Supplement 1): 4224.

https://doi.org/10.1182/blood-2024-211561

Published: 2024

Journal Articles

Single Cell Profiling of Ph-Positive Acute Lymphoblastic Leukemias Reveals Distinct Cells of Origin

Sogand Sajedi, Nicholas J. Short, Enes Dasdemir, Bofei Wang, Cedric Nasnas, Elias Jabbour, Hagop M. Kantarjian, Patrick K. Reville, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 4219.

https://doi.org/10.1182/blood-2024-210997

Published: 2024

Journal Articles

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Blood (2024) 144 (Supplement 1): 3817.

https://doi.org/10.1182/blood-2024-210779

Published: 2024

Journal Articles

Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML

Julie Braish, Guillermo Montalban-Bravo, Farhad Ravandi, Nicholas J. Short, Tapan M. Kadia, Maro Ohanian, Kelly S. Chien, Lucia Masarova, Koji Sasaki, Musa Yilmaz, Naval Daver, Gautam Borthakur, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 3209.

https://doi.org/10.1182/blood-2024-208536

Published: 2024

Journal Articles

Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation

Jayastu Senapati, Hagop M. Kantarjian, Guillermo Garcia-Manero, Nicholas J. Short, Fadi G. Haddad, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Joseph E. Jabbour, Naveen Pemmaraju, Amin M. Alousi, Elizabeth J. Shpall, Alexandre Bazinet, Kelly S. Chien, Danielle Hammond, Sherry Pierce, Farhad Ravandi, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 4251.

https://doi.org/10.1182/blood-2024-208121

Published: 2024

Journal Articles

Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker

Hussein A. Abbas, Bofei Wang, Jennifer Marvin-Peek, Bin Yuan, Araceli Isabella Garza, Jessica Lynn Root, Andrea Arruda, Yiwei Liu, Courtney D. DiNardo, Tapan M. Kadia, Naval Daver, Philip L Lorenzi, Koji Sasaki, Steven M. Kornblau, Mark D. Minden, Farhad Ravandi, Hagop M. Kantarjian, Patrick K. Reville

Blood (2024) 144 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2024-201725

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes

A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Trial in Progress

Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes

Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial

Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3 -Tyrosine Kinase Domain (TKD) Mutations

Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1- mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease

Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)

Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory

Single Cell Profiling of Ph-Positive Acute Lymphoblastic Leukemias Reveals Distinct Cells of Origin

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML

Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation

Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only